BioSpace News Archive

The Global Symposium of the ESPINEA® Academy in Karlsruhe, sponsored by joimax®, showcased how modern, advanced training for surgeons works.

The ablation devices market growth will be driven by growing preference for minimally invasive procedures. The rising occurrence of cancer and cardiovascular disorders globally will further fuel this growth.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new appointment to oversee the startup, strategic development and operational excellence in large-scale biologics production at its Boulder, Colorado site.

Baxter International Inc. (NYSE:BAX), a will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Select Medical Holdings Corporation will release the financial results for its fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 after the market closes.

Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year

Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the closing of its previously announced registered direct offering of 2,200,000 shares of its common stock

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, advises that one of its licensing partners, GSK, has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative colitis.

Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous system disorders, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $22.00 per share.